Table 7.

Univariate regression logistic analysis of the risk of cardiovascular mortality.

Group of factors	Factor	AF-HFpEF		AF-HFmrEF		AF-HFrEF
		OR (2.5–97.5)	p value	OR (2.5–97.5)	p value	OR (2.5–97.5)	p value
Laboratory tests	Total cholesterol			0.515 (0.291–0.851)	0.014
	International normalised ratio	2.825 (1.353–7.937)	0.013
	NT-proBNР	1.001 (1–1.002)	0.055
Habits and lifestyle	Balanced diet	0.355 (0.102–1.279)	0.099
Symptoms and syndromes	Anemia	5.618 (1.799–16.667)	0.002	4.219 (1.156–14.286)	0.022
	The number of specific signs of HF (pressure in the jugular veins, gallop rhythm, mixing the top of the jolt, wheezing in the lungs, and congestion in the lungs)	2.299 (1.441–3.676)	<0.001	1.567 (0.924–2.653)	0.089	1.497 (1.163–1.927)	0.002
	The number of typical symptoms of HF (dyspnea, fatigue, orthopnea, low effort tolerance, fatigue, edema, and apnoea)	1.961 (1.335–2.941)	0.001			1.346 (1.121–1.629)	0.002
Concomitant diseases	Endoscopy presence of erosive ulcerative lesions gastrointestinal mucosa					2.353 (0.951–5.464)	0.053
	Abnormal liver function			5.291 (1.425–18.519)	0.009
	Renal disease	4.184 (1.245–12.5)	0.013
CV system characteristics	Aortic valve insufficiency			2.907 (0.915–10.101)	0.075
	Arterial hypertension					2 (1.089–3.891)	0.032
	The duration of arterial hypertension (years)	1.066 (1.017–1.116)	0.006
	Cardiothoracic index (%)	1.597 (1.133–2.841)	0.036			1.161 (1.053–1.294)	0.004
	History of infarction and/or stroke	3.521 (1.222–11.494)	0.024
	Degree of pulmonary insufficiency					2.725 (1.269–5.882)	0.009
	Right atrium enlargement					3.546 (1.235–14.925)	0.04
	Degree of tricuspid insufficiency					1.37 (0.983–1.908)	0.061
	Echocardiographic signs of myocardial infarct (cicatricial changes and local conduction disturbance zones)	3.636 (1.233–10.526)	0.016			1.957 (1.129–3.509)	0.02
	Enlarged pulmonary trunk					2.375 (1.224–4.608)	0.01
	Prior major bleeding	6.494 (2.174–19.231)	0.001	3.891 (1.073–13.158)	0.03
Therapy	Regular use of anticoagulants					0.389 (0.225–0.666)	0.001
	Regular use of NOAC					0.42 (0.202–0.806)	0.013
	Regular use of peripheral vasodilators					4.587 (1.695–11.905)	0.002
	Regular use of statins	0.254 (0.083–0.724)	0.011			0.627 (0.366–1.08)	0.089
	Regular use of ACE inhibitors	0.22 (0.069–0.84)	0.015
	Permanent AF therapy with beta-blockers					0.404 (0.213–0.791)	0.006
	Permanent AF therapy with calcium channel blockers	0.172 (0.009–0.872)	0.091
	Rational therapy of HF					0.432 (0.238–0.757)	0.004
AF/HF features	HF developed after AF debut					0.463 (0.209–0.987)	0.05
	Age of AF debut					1.037 (1.011–1.067)	0.007
	Heart rate more than 100 beats per second			4.545 (0.917–33.333)	0.081
Scales and risks	CHA2DS2-VASc	1.385 (1.029–1.869)	0.031			1.163 (1.01–1.342)	0.037
	HAS-BLED	2.105 (1.305–3.425)	0.002	1.938 (1.238–3.175)	0.005	1.37 (1.098–1.715)	0.006